340B Drug Pricing Program
For more than 25 years, the 340B program has enabled hospitals that care for many low-income and uninsured patients to purchase certain outpatient drugs from drug companies at discounted prices
AHA to Eli Lilly and Company Re: Actions to Collect Data to Limit Distribution of Certain 340B Drugs
AHA expresses profound concern about actions Eli Lilly and Company is taking to collect data intended to limit the distribution of certain 340B drugs to hospitals and health systems.
AHA expresses profound concern about actions AztraZeneca is taking to collect data intended to limit the distribution of certain 340B drugs to hospitals and health systems.
AHA expresses profound concern about actions Novartis Corporation Global, is taking to collect data intended to limit the distribution of certain 340B drugs to hospitals and health systems.
AHA expresses profound concern about actions Merck is taking to collect data intended to limit the distribution of certain 340B drugs to hospitals and health systems.
The Centers for Medicare & Medicaid Services (CMS) today released the calendar year (CY) 2021 outpatient prospective payment system (OPPS)/ambulatory surgical center (ASC) proposed rule.
AHA statement on the CY OPPS proposed rule from Executive Vice President Tom Nickels.
The U.S. Court of Appeals for the District of Columbia Circuit overturned a 2018 district court decision that found the Department of Health and Human Services exceeded its statutory authority when it reduced 2018 and 2019 Medicare payment rates for many hospitals in the 340B Drug Pricing Program…
A statement on the 340B court decision from the AHA, AAMC and America’s Essential Hospitals
AHA expresses concern regarding recent action taken by three major drug manufacturers – Eli Lilly and Co., Merck and Sanofi – to limit the distribution of certain 340B drugs to our hospital members.